Cytomegalovirus (CMV) Research Projects
Antibody and viral determinants of protection against CMV infection following gB/MF59 vaccination
gB/MF59 immunization has proven moderately efficacious (~50%) at preventing primary HCMV infection in multiple phase II clinical trials. The goal of this study is to investigate the mechanism of protection of vaccine-elicited antibodies, as well as viral immune evasion thereof.
Sponsored by NIH: R21-AI136556
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys
Our goal is to advance congenital CMV vaccine research by defining the key immune responses and viral-host interactions that dictate primary fetal CMV transmission and disease in a highly relevant animal model.
Sponsored By: NIH: 1P01-AI129859
Use of a novel nonhuman primate model of congenital CMV for defining protective immunity.
We recently established a highly-relevant nonhuman primate model of congenital CMV
transmission through primary RhCMV infection of seronegative, breeding female rhesus monkeys. We are currently using this model to dissect the role of the maternal adaptive immune system in protection against intrauterine CMV transmission and virus-associated infant sequelae, establishing immunologic targets of a maternal CMV vaccine.
Sponsored By: NIH: DP2-HD075699
Humoral immune correlates of protection against congenital CMV and HSV transmission in HIV-infected women
We are enrolling women with a diagnosis of primary CMV infection during pregnancy. Samples are analyzed to evaluate the protective immune responses.
Spornsored by NIH: 1R21-AI147992